

=> b reg  
FILE 'REGISTRY' ENTERED AT 10:15:16 ON 01 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2008 HIGHEST RN 1076692-21-1  
DICTIONARY FILE UPDATES: 28 NOV 2008 HIGHEST RN 1076692-21-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 19  
L7 STR



VAR G1=0/S  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ELEVEL IS LIMITED  
ECOUNT IS E5 C E1 N AT 6

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE  
L9 80 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED 11980 ITERATIONS 80 ANSWERS  
SEARCH TIME: 00.00.01

=> b hcap  
FILE 'HCAPLUS' ENTERED AT 10:15:23 ON 01 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the

the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2008 VOL 149 ISS 23  
FILE LAST UPDATED: 30 Nov 2008 (20081130/ED)

HCplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l12 tct

L12 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2008 ACS ON STN  
 AN 2005:673296 HCPLUS  
 DN 143:172906  
 TI Preparation of tetraazabenzocouulene derivatives as vasopressin Vla and antagonists  
 IN Ryckmans, Thomas  
 PA Pfizer Limited, UK; Pfizer Inc.  
 SO PCT Int. Appl.; 53 pp.  
 C002:EN; PIXXD2  
 DP Patent  
 LA English  
 FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE  
 PI WO-2005084466 A1 200505728 200500-IB0000264 20050105  
 W: AF, BG, AL, AM, AI, AU, AZ, BA, BB, BG, BR, BM, BY, BE, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LZ, LU, LV, MA, MD, MG, MK, MM, MX, MZ, NA, NL,  
 NO, OM, PR, PT, RO, RU, SD, SE, SI, SK, SL, TM, TR, TZ, UA,  
 UZ, VN, ZA, ZM, ZW, AM  
 RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM  
 AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LZ, LU, MC, NL, PL, PI,  
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML  
 MV, SN, TD, TZ  
 CA-2554382 A1 20050728 2005CA-002554382 20050105  
 EP----1706409 A1 20061004 2005EP-000702410 20050105  
 R: AI, BE, CH, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PI,  
 IE, IS, LT, FI, RO, CZ, TR, BG, CT, DE, DK, PL, SK, IS  
 BR-2005064490 A1 200507012 2005BR-0000064490 20050105  
 JP-2007517857 I 20070705 2006JP-000548476 20050105  
 MX-2006PA07563 A 20060907 2006MX-PA0007563 20060629  
 US-20070167430 A1 20070719 2007US-000508878 20070322  
 PRAI 200504-00000000 P 20040113  
 2004US-044866P P 20040113  
 2005WI-IB0000263 M 20050105  
 OS CASREACT 143:172906; MARPAT 143:172906  
 GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds, I (X = NR or O (wherein P = H, alkyl or 502alkyl); W = N or CH; Y and Y1 = H, halo, OH, CF3, OCFS3, CN, NW2 alkyl, alkoxy or cycloalkyl; Ring A = a heterocyclic ring containing at least one N atom; Z = a direct link, alkyl or cycloalkyl; R1 = R2, OR2, NCOR2, SR4, etc.; R2, R4 = H, cycloalkyl, CF3, Ar or Het; Ar represents an aromatic ring, optionally fused to a heterocyclic ring; SR4 represents a sulfonate group, and R3 = a more complex group. Het represents a heterocyclic ring, optionally substituted with one or more groups, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups, useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, arrhythmia, hyperlipidemia), bronchitis (primary and secondary), bronchitis, asthma, including asthma, sickle cell anemia, intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease, were prepared. Thus, reacting 1-methoxybenzoic acid with the amine II, a protection group affected III. Some of the compds, I, are synthesized as library. All the exemplified compds, I, showed a Ki value of less than 500 nM when tested in screen 1.0 (VIA filter binding assay).

IT 860769-59-9P 860769-50-2P 860769-51-3P  
 860769-52-4P 860769-51-4P 860769-51-5P  
 860769-54-5P 860769-54-6P 860769-57-9P  
 860769-58-0P 860769-59-1P 860769-60-4P  
 860769-61-5P 860769-62-6P 860769-63-7P  
 860769-64-8P 860769-65-9P 860769-66-0P  
 860769-67-1P 860769-68-2P 860769-69-3P

L12 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
 860769-70-6P 860769-71-7P 860769-72-8P  
 860769-73-9P 860769-74-0P 860769-75-1P  
 860769-76-2P 860769-77-3P 860769-78-4P  
 860769-79-5P 860769-80-6P 860769-81-9P  
 860769-82-0P 860769-83-1P 860769-84-2P  
 860769-85-3P 860769-86-4P 860769-87-5P  
 860769-88-6P 860769-89-7P 860769-90-0P  
 860769-91-1P 860769-92-2P 860769-93-3P  
 860769-94-4P 860769-95-5P 860769-96-6P  
 860769-97-7P 860769-98-8P 860769-99-9P  
 860770-00-9P 860770-01-0P 860770-02-1P  
 860770-03-2P 860770-04-3P 860770-05-4P  
 860770-06-5P 860770-07-6P 860770-09-8P  
 860770-10-9P 860770-11-0P 860770-12-1P  
 860770-17-8P 860770-19-0P 860770-21-4P  
 860770-23-6P 860770-25-8P 860770-27-0P  
 860770-29-2P 860770-31-6P 860770-33-8P  
 860770-35-0P 860770-37-2P 860781-08-4P  
 RU, C002:EN; PREP (Preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of tetraazabenzocouulene derivs. as vasopressin Vla antagonists)  
 IT 860769-39-4P 860770-41-8P 860770-43-0P  
 860770-45-2P 860770-46-3P  
 RU, C002:EN; PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of tetraazabenzocouulene derivs. as vasopressin Vla antagonists)  
 IT 860769-40-5P 860770-42-9P 860770-44-1P  
 RU, C002:EN; SPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)  
 (preparation of tetraazabenzocouulene derivs. as vasopressin Vla antagonists)  
 RU 860769-49-9 HCPLUS  
 CN Methanone, (4-(8-chloro-5,6-dihydro-5-methyl-4H-1,2,4-triazolo(4,3-  
 a)(1,4)benzodiazepin-1-yl)-1-piperidinyl)-1H-indol-3-yl (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b uspatall  
FILE 'USPATFULL' ENTERED AT 10:15:42 ON 01 DEC 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 10:15:42 ON 01 DEC 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:15:42 ON 01 DEC 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr 113 tot

L13 ANSWER 1 OF 1 USPATFULL on STN  
 AN 2007:191249 USPATFULL  
 II Compounds useful in therapy  
 IN Rychnanský, Tomas, Kent, UNITED KINGDOM  
 PI US 200701167430 Al 2007-01-10  
 AI 2005US0-00588278 Al 20050105 (10)  
 2005US0-1B0000263 Al 20050105 (10)  
 20070322 PCT 371 date  
 PRAI 2004US-000000700 20040113  
 2004US-000544866P 20040213 (60)

DI UTILITY  
 FS APPLICATION  
 LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY,  
 10017-5612, US  
 C180 Number of Claims: 15  
 ECL Exempted Claim: 1  
 DRW No Drawings  
 LN.CNT 1690


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein: X represents NR or OR; R represents hydrogen, C.sub.1-8 alkyl or SO<sub>2</sub>sub.2; left brkt-bot.C..sub.1-8 alkyl:right brkt-top.; W represents N or CN; Y and Y' independently represent hydrogen, halogen, OH, CF<sub>3</sub>, sub.3, CN, NH, sub.2 C..sub.1-8 alkyl, C..sub.1-8 alkyl or C..sub.1-8 alkyl or C..sub.1-8 alkyl; A represents a heterocyclic ring containing at least one nitrogen atom; B represents a direct link, C..sub.1-8 alkyl or C..sub.3-8 cycloalkyl; R..sup.1 represents R..sup.2, OR..sup.2, OR..sup.3-R..sup.4, N(R..sup.2)[C..sub.1-8 alkyl], N(R..sup.2)[C..sub.1-8 alkyl], N(R..sup.2)[C..sub.1-8 alkyl], or SR..sup.4; R..sup.2 and R..sup.4 independently represent hydrogen, C..sub.1-8 alkyl, C..sub.3-8 cycloalkyl, or Ar; R..sup.3 represents a direct link or C..sub.1-8 alkyl; R..sup.4 on A, Ar represents an aromatic ring, optionally fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a heterocyclic ring optionally substituted with one or more groups as described below and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below at each occurrence C..sub.1-8 alkyl, C..sub.1-8 alkylene and C..sub.3-8 cycloalkyl may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het, C..sub.1-8 alkyl, C..sub.1-8 alkylene and C..sub.3-8 cycloalkyl referred to the present invention are selected from the following: C..sub.1-8 alkyl, C..sub.1-8 alkyl, C..sub.1-8 alkyl, C..sub.1-8 alkyl, C..sub.1-8 alkyl, CN, CF<sub>3</sub>, NH, sub.2 and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preeclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 860769-49-3P 860769-50-2P 860769-51-2P  
 860769-52-4P 860769-53-5P 860769-54-6P  
 860769-55-7P 860769-56-8P 860769-57-9P  
 860769-58-0P 860769-59-1P 860769-60-4P  
 860769-61-5P 860769-62-6P 860769-63-7P  
 860769-64-8P 860769-65-9P 860769-66-0P  
 860769-67-1P 860769-68-2P 860769-69-3P  
 860769-70-6P 860769-71-7P 860769-72-8P  
 860769-73-9P 860769-74-0P 860769-75-1P  
 860769-76-2P 860769-77-3P 860769-78-4P  
 860769-79-5P 860769-80-6P 860769-81-7P  
 860769-82-0P 860769-83-1P 860769-84-2P  
 860769-85-3P 860769-86-4P 860769-87-5P  
 860769-88-6P 860769-89-7P 860769-90-0P  
 860769-91-1P 860769-92-2P 860769-93-3P  
 860770-00-4P 860770-05-5P 860770-06-6P  
 860769-97-7P 860769-98-8P 860769-99-9P  
 860770-00-0P 860770-01-0P 860770-02-1P  
 860770-03-2P 860770-04-3P 860770-05-4P  
 860770-06-5P 860770-07-6P 860770-09-8P

L13 ANSWER 1 OF 1 USPATFULL on STN (Continued)  
 860770-11-2P 860770-13-4P 860770-15-6P  
 860770-17-8P 860770-19-0P 860770-21-4P  
 860770-23-6P 860770-24-7P 860770-25-8P  
 860770-25-0P 860770-31-6P 860770-33-8P  
 860770-35-0P 860770-37-2P 860781-08-4P  
 (prepn. of tetraazabenzozulene derivs. as vasopressin V<sub>1</sub>a antagonists)  
 IT 860770-39-4P 860770-41-8P 860770-43-0P  
 860770-45-2P 860770-46-3P  
 (prepn. of tetraazabenzozulene derivs. as vasopressin V<sub>1</sub>a antagonists)  
 IT 860769-49-9P  
 (preparation of tetraazabenzozulene derivs. as vasopressin V<sub>1</sub>a antagonists)  
 RN 860769-49-9 USPATFULL  
 CN Methanone, [(4-(8-chloro-5,6-dihydro-5-methyl-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepin-1-yl)-1-piperidinyl]-1H-indol-3-yl- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:06:27 ON 01 DEC 2008)  
FILE 'HCAPLUS' ENTERED AT 10:07:07 ON 01 DEC 2008  
L1 1 US20070167430/PN  
FILE 'REGISTRY' ENTERED AT 10:07:22 ON 01 DEC 2008  
FILE 'HCAPLUS' ENTERED AT 10:07:22 ON 01 DEC 2008  
L2 TRA L1 1- RN : 100 TERMS  
FILE 'REGISTRY' ENTERED AT 10:07:23 ON 01 DEC 2008  
L3 100 SEA L2  
L4 83 L3 AND NRRS>=3  
L5 83 L4 AND NC5/ES  
L6 81 L5 AND N2CNC-C6-NC2NC3/ES  
L7 STR  
L8 6 L7  
L9 80 L7 FULL  
SAV TEM J878C1/A L9  
L10 80 L9 AND L3  
FILE 'HCAOLD' ENTERED AT 10:14:03 ON 01 DEC 2008  
L11 0 L9  
FILE 'HCAPLUS' ENTERED AT 10:14:08 ON 01 DEC 2008  
L12 1 L9  
FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 10:14:33 ON 01 DEC 2008  
L13 1 L9

=>